This Is What Whales Are Betting On Gilead Sciences
This Is What Whales Are Betting On Gilead Sciences
High-rolling investors have positioned themselves bullish on Gilead Sciences (NASDAQ:GILD), and it's important for retail traders to take note.\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in GILD often signals that someone has privileged information.
大佬們看好吉利德科學（納斯達克：GILD），零售交易者需要注意。我們從Benzinga的公開期權數據跟蹤中了解到這一情況。這些投資者的身份不確定，但GILD的這種重大變動通常意味着有人掌握了內幕信息。
Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern.
今天，Benzinga的期權掃描器在吉利德科學中發現9筆期權交易。這不是典型的交易模式。
The sentiment among these major traders is split, with 55% bullish and 33% bearish. Among all the options we identified, there was one put, amounting to $27,798, and 8 calls, totaling $322,062.
這些主要交易者的情緒分歧，55%看漲，33%看淡。在我們發現的所有期權中，有1個看跌，金額爲$27,798，8個看漲，總額爲$322,062。
Expected Price Movements
預期價格波動
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $55.0 to $78.0 for Gilead Sciences during the past quarter.
分析這些合約的成交量和持倉量，似乎大佬們在過去的一個季度一直在關注吉利德科學的股價窗口，範圍在$55.0至$78.0之間。
Insights into Volume & Open Interest
成交量和持倉量分析
In today's trading context, the average open interest for options of Gilead Sciences stands at 1447.83, with a total volume reaching 4,990.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Gilead Sciences, situated within the strike price corridor from $55.0 to $78.0, throughout the last 30 days.
在今天的交易環境中，吉利德科學期權的平均持倉量爲1447.83，總成交量達到4,990.00。下圖展示了吉利德科學高價值交易的看漲和看跌期權成交量和持倉量的發展情況，範圍在期權執行價格從$55.0至$78.0之間的之間，持續最近30天。
Gilead Sciences 30-Day Option Volume & Interest Snapshot
吉利德科學30天期權成交量和未平倉合約快照
Noteworthy Options Activity:
值得注意的期權活動：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | CALL | TRADE | BEARISH | 08/16/24 | $1.66 | $1.65 | $1.65 | $77.50 | $62.7K | 2.5K | 149 |
| GILD | CALL | SWEEP | BULLISH | 08/02/24 | $1.05 | $1.0 | $1.05 | $78.00 | $52.5K | 18 | 761 |
| GILD | CALL | TRADE | BULLISH | 01/17/25 | $15.8 | $14.9 | $15.8 | $60.00 | $47.4K | 925 | 30 |
| GILD | CALL | SWEEP | BULLISH | 08/02/24 | $0.77 | $0.75 | $0.77 | $78.00 | $34.8K | 18 | 2.6K |
| GILD | CALL | TRADE | NEUTRAL | 01/17/25 | $9.7 | $9.3 | $9.51 | $70.00 | $33.2K | 3.0K | 41 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | 看漲 | 交易 | 看淡 | 08/16/24 | $1.66 | $1.65 | $1.65 | $77.50 | $62.7千美元 | 2.5千 | 149 |
| GILD | 看漲 | SWEEP | 看好 | 08/02/24 | $1.05 | $1.0 | $1.05 | 每桶78.00美元 | $52.5K | 18 | 761 |
| GILD | 看漲 | 交易 | 看好 | 01/17/25 | $15.8 | $14.9 | $15.8 | $60.00 | $47.4K | 925 | 30 |
| GILD | 看漲 | SWEEP | 看好 | 08/02/24 | $0.77 | 0.75美元 | $0.77 | 每桶78.00美元 | $34.8K | 18 | 2.6K |
| GILD | 看漲 | 交易 | 中立 | 01/17/25 | 9.7 | $9.3 | $9.51 | 70.00美元 | $33200 | 3.0K | 41 |
About Gilead Sciences
關於吉利德科學
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
吉利德科學公司開發和推廣治療威脅生命的傳染病的療法，其核心產品組合主要集中在治療艾滋病毒和乙型及丙型肝炎方面。通過收購 Corus Pharma、Myogen、CV Therapeutics、Arresto Biosciences 和 Calistoga，公司將業務口徑拓展至肺部和心血管疾病以及癌症治療領域。吉利德對 Pharmasset 的收購帶來了治療丙型肝炎藥物 Sovaldi 的權利，這也是組合藥物 Harvoni 的一部分，而 Kite、Forty Seven 和 Immunomedics 的收購則提高了吉利德在細胞治療和非細胞治療腫瘤領域中的曝光度。
After a thorough review of the options trading surrounding Gilead Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
在全面審查Gilead Sciences的期權交易之後，我們進一步考察了該公司的業績表現。這包括對其當前市場狀況和表現評估。
Gilead Sciences's Current Market Status
吉利德科學的當前市場狀況
- With a volume of 3,365,071, the price of GILD is up 2.73% at $75.51.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 14 days.
- GILD的成交量爲3,365,071，價格上漲了2.73%，達到75.51美元。
- RSI因子暗示底層股票可能被超買。
- 下一輪業績預計將在14天內發佈。
What Analysts Are Saying About Gilead Sciences
分析師對吉利德科學的看法
3 market experts have recently issued ratings for this stock, with a consensus target price of $79.0.
3位市場專家最近對該股發表了評級，目標價爲79.0美元。
- An analyst from Raymond James upgraded its action to Outperform with a price target of $93.
- An analyst from Cantor Fitzgerald has decided to maintain their Neutral rating on Gilead Sciences, which currently sits at a price target of $70.
- Reflecting concerns, an analyst from RBC Capital lowers its rating to Sector Perform with a new price target of $74.
- 來自雷蒙德詹姆斯的分析師將其評級升級爲增持，並將目標價設定爲93美元。
- Cantor Fitzgerald的一位分析師決定維持對吉利德科學中性的評級，目前的目標價爲70美元。
- 反映擔憂，RBC Capital的一位分析師將其評級下調至板塊表現（Sector Perform），並設立了一個新目標價74美元。
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Gilead Sciences with Benzinga Pro for real-time alerts.
期權交易涉及更高的風險，但也提供了更高的利潤潛力。精明的交易者通過持續教育、戰略性交易調整、利用各種指標並保持市場動態的關注來減輕這些風險。通過Benzinga Pro獲取最新的吉利德科學期權交易實時提醒。